Business Description
Hua Medicine
ISIN : KYG4644K1022
Total Employee Number:
328Compare
Compare
Traded in other countries / regions
02552.Hong KongHUMDF.USA IPO Date
2018-09-14Description
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.03 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -4.36 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.76 | |||||
Beneish M-Score | 2.2 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 200.2 | |||||
3-Year EPS without NRI Growth Rate | 13.6 | |||||
3-Year FCF Growth Rate | 39.5 | |||||
3-Year Book Growth Rate | 51.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.79 | |||||
9-Day RSI | 55.83 | |||||
14-Day RSI | 54 | |||||
3-1 Month Momentum % | -23.17 | |||||
6-1 Month Momentum % | -19.23 | |||||
12-1 Month Momentum % | -29.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.34 | |||||
Quick Ratio | 3.05 | |||||
Cash Ratio | 2.66 | |||||
Days Inventory | 169.45 | |||||
Days Sales Outstanding | 55.25 | |||||
Days Payable | 109.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 | |||||
Shareholder Yield % | -3.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.67 | |||||
Operating Margin % | -14.78 | |||||
Net Margin % | -16.25 | |||||
EBITDA Margin % | -12.65 | |||||
FCF Margin % | -5.2 | |||||
OCF Margin % | -4.98 | |||||
ROE % | -10.59 | |||||
ROA % | -7.34 | |||||
ROIC % | -31.4 | |||||
3-Year ROIIC % | -31.82 | |||||
ROC (Joel Greenblatt) % | -50.73 | |||||
ROCE % | -8.21 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 2.01 | |||||
PS Ratio | 3.47 | |||||
PB Ratio | 2.23 | |||||
Price-to-Tangible-Book | 2.27 | |||||
EV-to-EBIT | -15.44 | |||||
EV-to-EBITDA | -18.25 | |||||
EV-to-Revenue | 2.31 | |||||
EV-to-FCF | -44.36 | |||||
Price-to-GF-Value | 0.3 | |||||
| Price-to-Net-Current-Asset-Value | 2.67 | |||||
| Price-to-Net-Cash | 4 | |||||
Earnings Yield (Greenblatt) % | -6.48 | |||||
FCF Yield % | -1.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hua Medicine Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 742.64 | ||
| EPS (TTM) (HK$) | -0.134 | ||
| Beta | 1.2505 | ||
| 3-Year Sharpe Ratio | 0.19 | ||
| 3-Year Sortino Ratio | 0.3 | ||
| Volatility % | 48.39 | ||
| 14-Day RSI | 54 | ||
| 14-Day ATR (HK$) | 0.149084 | ||
| 20-Day SMA (HK$) | 2.47575 | ||
| 12-1 Month Momentum % | -29.01 | ||
| 52-Week Range (HK$) | 1.97 - 4.95 | ||
| Shares Outstanding (Mil) | 996.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hua Medicine Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hua Medicine Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hua Medicine Frequently Asked Questions
What is Hua Medicine(HKSE:02552)'s stock price today?
The current price of HKSE:02552 is HK$2.56. The 52 week high of HKSE:02552 is HK$4.95 and 52 week low is HK$1.97.
When is next earnings date of Hua Medicine(HKSE:02552)?
The next earnings date of Hua Medicine(HKSE:02552) is .
Does Hua Medicine(HKSE:02552) pay dividends? If so, how much?
Hua Medicine(HKSE:02552) does not pay dividend.
Articles on Hua Medicine
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers